Literature DB >> 16998646

Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.

Lindsay R Pattison1, Mark R Kotter, Dean Fraga, Raphael M Bonelli.   

Abstract

Huntington's disease (HD) is a devastating autosomal dominant disorder characterized by progressive motor and neuropsychological symptoms. Evidence implicating the apoptotic cascades as a possible cause for the neurodegeneration seen in HD has directed researchers toward investigating therapeutic treatments targeting caspases and other proapoptotic factors. Cellular and murine models, which have demonstrated that caspase-mediated cleavage could be the cause for the neurodegeneration seen in HD, have evoked more research investigating the possible inhibition of apoptosis in HD. In particular, minocycline, a tetracycline-derived antibiotic that has been shown to increase survival in transgenic mouse models of HD, exhibits a neuroprotective feature in HD and demonstrates an anti-inflammatory as well as an anti-microbial effect by inhibiting microglial activation known to cause apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998646     DOI: 10.1007/s00415-006-0198-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  52 in total

1.  Minocycline slows progress of Huntington's disease in mice

Authors: 
Journal:  BMJ       Date:  2000-07-08

2.  Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta.

Authors:  T Nakagawa; H Zhu; N Morishima; E Li; J Xu; B A Yankner; J Yuan
Journal:  Nature       Date:  2000-01-06       Impact factor: 49.962

3.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

4.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.

Authors:  Y He; S Appel; W Le
Journal:  Brain Res       Date:  2001-08-03       Impact factor: 3.252

5.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

6.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.

Authors:  R R Brinkman; M M Mezei; J Theilmann; E Almqvist; M R Hayden
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

7.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

8.  Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Authors:  Cheryl L Wellington; Lisa M Ellerby; Claire-Anne Gutekunst; Danny Rogers; Simon Warby; Rona K Graham; Odell Loubser; Jeremy van Raamsdonk; Roshni Singaraja; Yu-Zhou Yang; Juliette Gafni; Dale Bredesen; Steven M Hersch; Blair R Leavitt; Sophie Roy; Donald W Nicholson; Michael R Hayden
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

9.  Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Authors:  C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

10.  Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner.

Authors:  E A Slee; M T Harte; R M Kluck; B B Wolf; C A Casiano; D D Newmeyer; H G Wang; J C Reed; D W Nicholson; E S Alnemri; D R Green; S J Martin
Journal:  J Cell Biol       Date:  1999-01-25       Impact factor: 10.539

View more
  15 in total

1.  Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.

Authors:  Jordi Creus-Muncunill; Anna Guisado-Corcoll; Veronica Venturi; Lorena Pantano; Georgia Escaramís; Marta García de Herreros; Maria Solaguren-Beascoa; Ana Gámez-Valero; Cristina Navarrete; Mercè Masana; Franc Llorens; Daniela Diaz-Lucena; Esther Pérez-Navarro; Eulàlia Martí
Journal:  Acta Neuropathol       Date:  2021-02-06       Impact factor: 17.088

2.  Meclizine is neuroprotective in models of Huntington's disease.

Authors:  Vishal M Gohil; Nicolas Offner; James A Walker; Sunil A Sheth; Elisa Fossale; James F Gusella; Marcy E MacDonald; Christian Neri; Vamsi K Mootha
Journal:  Hum Mol Genet       Date:  2010-10-25       Impact factor: 6.150

3.  Inhibitors of metabolism rescue cell death in Huntington's disease models.

Authors:  Hemant Varma; Richard Cheng; Cindy Voisine; Anne C Hart; Brent R Stockwell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

4.  Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma.

Authors:  Hani Levkovitch-Verbin; Yael Waserzoog; Shelly Vander; Daria Makarovsky; Ilia Piven
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-25       Impact factor: 3.117

5.  Similarities and differences between primary and secondary degeneration of the optic nerve and the effect of minocycline.

Authors:  Hani Levkovitch-Verbin; Oriel Spierer; Shelly Vander; Rima Dardik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-13       Impact factor: 3.117

6.  Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease.

Authors:  Rodolfo G Gatto; Yaping Chu; Allen Q Ye; Steven D Price; Ehsan Tavassoli; Andrea Buenaventura; Scott T Brady; Richard L Magin; Jeffrey H Kordower; Gerardo A Morfini
Journal:  Hum Mol Genet       Date:  2015-06-29       Impact factor: 6.150

Review 7.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

8.  Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion.

Authors:  Zhi-You Cai; Yong Yan; Shan-Quan Sun; Jun Zhang; Liang-Guo Huang; Ning Yan; Fang Wu; Jie-Ying Li
Journal:  Neurosci Bull       Date:  2008-10       Impact factor: 5.203

Review 9.  Neuroprotection for Huntington's disease: ready, set, slow.

Authors:  Steven M Hersch; H Diana Rosas
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

10.  Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease.

Authors:  Barbara Biscaro; Olle Lindvall; Giuseppina Tesco; Christine T Ekdahl; Roger M Nitsch
Journal:  Neurodegener Dis       Date:  2012-05-08       Impact factor: 2.977

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.